One attractive paradigm of anticancer strategies is to target oncogenes for sensitization of tumor cells to apoptosis. The rationale is that onco-proteins rely on other factors to maintain homeostasis or promote cancer cell survival. Disruption of one of coordinating proteins would trigger an apoptotic crisis in cancer cells. Oncogenic Ras has been discovered in about 30-40% of human cancers. However, inhibitors targeting mutated Ras have proved not to be effective clinically. Recently, the focus has been on finding signaling pathways that are downstream of or parallel with Ras, and are essential for cancer cells to survive. In the effort to identify the apoptotic partners of mutated Ras, studies showed that loss of PKC, together with mutated Ras, are synthetically lethal in many types of tumors. Recently, we made the novel observation that loss of different PKC isoforms differentially sensitized cells expressing mutated ras to apoptosis. In particular, we identified that co-suppression of PKC?/? were critical for the induction of apoptosis in cancer cells harboring mutated ras, in which PI3K/Akt function downstream of Ras to mobilized two signaling pathways: one was via upregulating ROS and ER stress-mediated UPR for switching on the apoptotic machinery;and another one was through activating PKC?, resulting in p73 phosphorylation and PUMA/NOXA upregulation. In this renewal application, we will investigate the molecular mechanisms of our novel observation of how Ras, upon loss of PKC??/?, differentially utilizes its downstream effector pathways to selectively sensitize tumor cells to apoptosis, with less or no toxicity to normal cells or surrounding tissues. We will determine how ROS and PKC??/p73 pathways are being redirected by aberrant Ras/PI3K/Akt to activate cell death program after co-suppression of PKC??/?. Thus, the hypothesis to be tested is that upon co-knockdown of PKC??/?, PI3K/Akt are key players in the induction of Ras-mediated apoptosis, which is via perturbing redox homeostasis as well as through activating PKC??/ p73-mediated apoptotic network. Accordingly, 4 Specific Aims are formed.
Aim 1 will study the mechanisms by which ROS is upregulated in cells expressing aberrant ras or PI3K/Akt upon co- suppression of PKC??/?.
Aim 2 will determine the mechanisms by which ROS induces ER-stress/UPR activation in cells expressing aberrant ras or PI3K/Akt upon co-suppression of PKC??/?.
In Aim 3, we will determine the role of p73 in the sensitization of cells expressing aberrant ras or PI3K/Akt to apoptosis after co- knockdown of PKC??/?.
In Aim 4, we will determine the pro-apoptotic effect in cells expressing aberrant ras or PI3K/Akt in vitro and in vivo after co-suppression of PKC??/?. The outcomes of our research will reveal molecules involved in this synthetic lethal interaction between Ras mutations and loss of PKC??/?, which will provide the potential information for designing more effective drugs to treat human cancers harboring aberrant ras or PI3K/Akt.
Mutations in oncogenes are common in human tumors. Activating mutations in the ras oncogenes contribute to the formation of more than 30% of human malignancies. Attempts to target mutated Ras with chemical inhibitors have not been successful. Recently, there has been increasing attentions in finding and targeting signaling pathways that function downstream of or parallel with Ras. We discovered the synthetic lethal interaction between aberrant Ras and loss of PKC??/?. The proposal aims at the elucidation of the underlying mechanisms by which PI3K/Akt functions downstream of Ras upon co-suppression of PKC??/? to induce apoptosis via activating p73/PUMA/NOXA signaling as well as NADPH/ROS/UPR pathway. The outcomes of our proposal may provide new strategies for the treatment with cancer harboring aberrant Ras or PI3K/Akt.
|Ganapathy, Suthakar; Li, Ping; Fagman, Johan et al. (2016) Low doses of arsenic, via perturbing p53, promotes tumorigenesis. Toxicol Appl Pharmacol 306:98-104|
|Restuccia, Agnese; Yang, Feikun; Chen, Changyan et al. (2016) Mps1 is SUMO-modified during the cell cycle. Oncotarget 7:3158-70|
|Peng, Bo; Ganapathy, Suthakar; Shen, Ling et al. (2015) Targeting Bcl-2 stability to sensitize cells harboring oncogenic ras. Oncotarget 6:22328-37|
|Nishioka, T; Luo, L-Y; Shen, L et al. (2014) Nicotine increases the resistance of lung cancer cells to cisplatin through enhancing Bcl-2 stability. Br J Cancer 110:1785-92|
|Choi, Byeong Hyeok; Chen, Yan; Dai, Wei (2013) Chromatin PTEN is involved in DNA damage response partly through regulating Rad52 sumoylation. Cell Cycle 12:3442-7|
|Shen, Ling; Nishioka, Takashi; Guo, Jinjin et al. (2012) Geminin functions downstream of p53 in K-ras-induced gene amplification of dihydrofolate reductase. Cancer Res 72:6153-62|
|Shen, Ling; Kim, Sung-Hoon; Chen, Chang Yan (2012) Sensitization of human pancreatic cancer cells harboring mutated K-ras to apoptosis. PLoS One 7:e40435|
|Zhu, Tongbo; Chen, Lihua; Du, Wei et al. (2010) Synthetic Lethality Induced by Loss of PKC Ã½Ã½ and Mutated Ras. Genes Cancer 1:142-151|
|Guo, Jinjin; Zhu, Tongbo; Chen, Lihua et al. (2010) Differential Sensitization of Different Prostate Cancer Cells to Apoptosis. Genes Cancer 1:836-846|
|Reiterer, Gudrun; Chen, Lihua; Tassef, Ryan et al. (2010) RAF associates with phosphorylated nuclear BubR1 during endoreduplication induced by JAK inhibition. Cell Cycle 9:3297-304|
Showing the most recent 10 out of 18 publications